Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-s···【more】
Release date：2024-08-09Recommended：212
Exkivity (mobocertinib) is a tyrosine kinase inhibitor (TKI) used to treat non-s···【more】
Release date：2024-08-09Recommended：194
Capmatinib targets the activity of MET receptors and blocks the tumor cell growt···【more】
Release date：2024-08-08Recommended：230
Capmatinib is an oral form of c-Met kinase inhibitor with selective and ATP-comp···【more】
Release date：2024-08-08Recommended：222
Capmatinib prevents cancer cell growth by inhibiting the activity of MET tyrosin···【more】
Release date：2024-08-08Recommended：222
Exkivityimproves patient outcomes by inhibiting specific mutant kinases and bloc···【more】
Release date：2024-08-08Recommended：185
Capmatinib is a selective c-Met kinase inhibitor with significant anti-tumor act···【more】
Release date：2024-08-08Recommended：223
Exkivity effectively inhibits the growth and spread of tumor cells by precisely ···【more】
Release date：2024-08-08Recommended：228
Capmatinib is a MET inhibitor developed by Novartis specifically for patients wi···【more】
Release date：2024-08-08Recommended：178
Exkivityis an innovative third-representative dermal growth factor receptor (EGF···【more】
Release date：2024-08-08Recommended：175
Capmatinib is an oral kinase inhibitor targeting mutations in the MET gene, prim···【more】
Release date：2024-08-08Recommended：196
Capmatinib is a targeted therapy for the treatment of non-small cell lung cancer···【more】
Release date：2024-08-08Recommended：220
